结直肠癌 中国就医指南

Colorectal cancer (CRC) is a malignant neoplasm arising from the epithelial lining of the colon or rectum. It typically develops from precancerous adenomatous polyps through a stepwise accumulation of genetic and epigenetic alterations—most notably in the APC, KRAS, TP53, and mismatch repair (MMR) genes—culminating in uncontrolled cellular proliferation, invasion, and metastasis. The disease follows the well-established adenoma-carcinoma sequence in ~85% of sporadic cases; however, hereditary forms—including Lynch syndrome (hereditary non-polyposis colorectal cancer) and familial adenomatous polyposis (FAP)—account for 5–10% of diagnoses and confer significantly elevated lifetime risk. Globally, CRC is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, with over 1.9 million new cases and nearly 935,000 deaths annually (GLOBOCAN 2022). In China, incidence has risen sharply over the past two decades—now exceeding 550,000 new cases per year—driven by urbanization, aging populations, and shifts toward Westernized diets high in red/processed meats, low in dietary fiber, and associated with sedentary lifestyles. Key modifiable risk factors include obesity, type 2 diabetes, heavy alcohol consumption, smoking, and long-term inflammatory bowel disease (e.g., ulcerative colitis or Crohn’s colitis). Non-modifiable risks encompass age (>50 years), personal or family history of CRC or advanced adenomas, and inherited syndromes. Early-stage CRC is often asymptomatic, underscoring the critical importance of screening—particularly fecal immunochemical testing (FIT), colonoscopy, and multi-target stool DNA tests. When symptoms emerge, they may include persistent changes in bowel habits (e.g., diarrhea, constipation, or narrowing of stool), rectal bleeding or blood in stool, unexplained abdominal discomfort or cramping, iron-deficiency anemia, unintentional weight loss, or fatigue. Diagnosis relies on endoscopic visualization with biopsy confirmation, supplemented by cross-sectional imaging (CT/MRI) and molecular profiling (e.g., MSI/MMR status, RAS/BRAF mutations) to guide prognosis and therapy. Treatment is multidisciplinary: localized disease is primarily managed with surgical resection (laparoscopic or robotic-assisted colectomy/low anterior resection); locally advanced or node-positive cases often require adjuvant chemotherapy (e.g., FOLFOX or CAPEOX); and metastatic disease may involve systemic therapy (chemotherapy, targeted biologics like anti-EGFR or anti-VEGF agents), immunotherapy (for MSI-H/dMMR tumors), and metastasectomy when feasible. Beyond survival, CRC profoundly impacts quality of life—physically (bowel dysfunction, stoma-related challenges, neuropathy), psychologically (anxiety, depression, body image concerns), socially (work disruption, caregiving burden), and economically (out-of-pocket costs, lost productivity). Survivorship care emphasizes surveillance colonoscopy, nutritional support, physical rehabilitation, and psychosocial counseling to mitigate long-term sequelae and optimize functional recovery.

# 结直肠癌治疗方案与费用明细（消化内科）

一、非手术治疗方案

适用人群：早期不可手术者、高龄/合并严重基础病、局部晚期新辅助治疗前、术后辅助治疗或姑息维持。

• •化疗（FOLFOX/FOLFIRI）：6周期，含奥沙利铂+5-FU+亚叶酸钙；费用：3.8–6.2万元（含药费、输注费、血常规/肝肾功能监测等）
• •靶向治疗（RAS野生型）：西妥昔单抗/帕尼单抗联合化疗；费用：12.5–22.0万元/年（含基因检测2800元、每月用药及影像随访）
• •免疫治疗（MSI-H/dMMR型）：帕博利珠单抗；费用：18.6–24.0万元/年（含PD-L1/MSI检测3200元、每3周给药及不良反应管理）

二、手术与介入治疗方案

适用人群：Ⅰ–Ⅲ期可切除患者、局部进展期经新辅助后转化成功者。

• •腹腔镜根治术（右半/左半/直肠）：含淋巴结清扫、标本送检；术前检查（肠镜+增强CT+心肺评估）：4200–6500元；手术总费用：5.5–9.8万元
• •经肛微创切除（TAMIS/TA-TME）：适用于早期低位直肠癌；总费用：4.3–7.1万元（含术中病理快速诊断）

三、晚期/耐药/并发症专项方案

• •肝/肺转移灶射频消融（RFA）或微波消融：单灶≤3cm，费用：2.6–4.0万元/次
• •多线治疗失败后最佳支持治疗（含镇痛、营养支持、造口护理）：月均费用：2800–5200元

四、方案快速选择指南

• •预算有限、早期无转移：首选腹腔镜手术（5.5万起），性价比最优
• •RAS/BRAF突变、无法手术：靶向+化疗组合（首年约15万）
• •MSI-H晚期患者：免疫治疗为一线优选（长期生存获益显著）
• •高龄/心肺功能差：姑息性支架置入+个体化低强度化疗（总费用≤4万元）